The lesson from Festo is that during patent prosecution, what you say (or don't say) and what you do (or don't do) will be used against you.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gogoris, A.C. & Lee, S.S. Festo and the US Supreme Court: be careful what you wish for. Nat. Biotechnol. 20, 845–846 (2002).
Amgen, Inc. v. Hoechst Marion Roussel, Inc., 287 F.Supp.2d 126 (D. Mass. 2003).
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 234 F.3d 558 (Fed. Cir. 2000).
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002).
Glaxo Wellcome, Inc. v. Eon Labs Mfg., 2002 U.S. Dist. LEXIS 14923 (S.D.N.Y. Aug. 13, 2002).
Glaxo Wellcome, Inc. v. Impax Labs., Inc., 220 F.Supp.2d 1089 (N.D. Cal. 2002); affirmed by Glaxo v. Impax, 2004 U.S. App. LEXIS 1324 (Fed. Cir. Jan. 29, 2004).
SmithKline Beecham Corp. v. Excel Pharm., Inc., 214 F.Supp.2d 581 (E.D. Va. 2002); vacated and remanded by SmithKline v. Excel, 2004 U.S. App. LEXIS 1323 (Fed. Cir. Jan. 29, 2004).
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 344 F.3d 1359 (Fed. Cir. 2003).
Ranbaxy Pharmaceuticals, Inc. v. Apotex, Inc., 350 F.3d 1235 (Fed. Cir. 2003).
Mycogen Plant Sci. v. Monsanto Co., 2004 U.S. App. LEXIS 3001 (Fed. Cir. Feb 20, 2004).
Toupin, J. & Whealan, J. Effects of Festo decision on USPTO Operations. http://www.uspto.gov/web/offices/com/advisory/ acrobat/ppacpres2-01.pdf (February, 28, 2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones, P. US courts struggle with new patent infringement standards. Nat Biotechnol 22, 461–463 (2004). https://doi.org/10.1038/nbt0404-461
Issue Date:
DOI: https://doi.org/10.1038/nbt0404-461